Posted by Michael Wonder on 09 Sep 2021
Merck’s Keytruda (pembrolizumab) approved in China in combination with chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic oesophageal or gastro-oesophageal junction carcinoma
7 September 2021 - Keytruda is now approved for eight indications across five different types of cancer in China.
Merck today announced that Keytruda has been approved by the National Medical Products Administration in China in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or gastro-oesophageal junction.
